Demonstration of the Blood-Stage Plasmodium Falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. Falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01

Background: Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials. Efficacy testing of blood-stage malaria parasite vaccines, however, has generally relied on larger-scale phase 2b field trials in malaria-endemic populations. We report the use of a blood-stage P. falciparum CHMI model to assess blood-stage vaccine candidates, using their impact on the parasite multiplication rate (PMR) as the primary efficacy end point.

Methods: Fifteen healthy United Kingdom adult volunteers were vaccinated with FMP2.1, a protein vaccine that is based on the 3D7 clone sequence of apical membrane antigen 1 (AMA1) and formulated in Adjuvant System 01 (AS01). Twelve vaccinees and 15 infectivity controls subsequently underwent blood-stage CHMI. Parasitemia was monitored by quantitative real-time polymerase chain reaction (PCR) analysis, and PMR was modeled from these data.

Results: FMP2.1/AS01 elicited anti-AMA1 T-cell and serum antibody responses. Analysis of purified immunoglobulin G showed functional growth inhibitory activity against P. falciparum in vitro. There were no vaccine- or CHMI-related safety concerns. All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR.

Conclusions: FMP2.1/AS01 demonstrated no efficacy after blood-stage CHMI. However, the model induced highly reproducible infection in all volunteers and will accelerate proof-of-concept testing of future blood-stage vaccine candidates.

Clinical Trials Registration: NCT02044198.

Citing Articles

Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.

Kessy E, Olotu A Malar J. 2025; 24(1):33.

PMID: 39893367 PMC: 11786456. DOI: 10.1186/s12936-025-05277-x.

Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.

Thiam L, McHugh K, Ba A, Li R, Guo Y, Pouye M NPJ Vaccines. 2024; 9(1):198.

PMID: 39448626 PMC: 11502735. DOI: 10.1038/s41541-024-00986-x.

Malaria vaccines: a new era of prevention and control.

Duffy P, Gorres J, Healy S, Fried M Nat Rev Microbiol. 2024; 22(12):756-772.

PMID: 39025972 DOI: 10.1038/s41579-024-01065-7.

How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays.

Miura K Vaccines (Basel). 2024; 12(6).

PMID: 38932315 PMC: 11209467. DOI: 10.3390/vaccines12060586.

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama I, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L Immunity. 2024; 57(6):1215-1224.e6.

PMID: 38788711 PMC: 7616646. DOI: 10.1016/j.immuni.2024.05.001.

References

Duncan C, Draper S . Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012; 86(4):561-5. PMC: 3403771. DOI: 10.4269/ajtmh.2012.11-0504. View

Boyle M, Reiling L, Feng G, Langer C, Osier F, Aspeling-Jones H . Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015; 42(3):580-90. PMC: 4372259. DOI: 10.1016/j.immuni.2015.02.012. View

Sheehy S, Spencer A, Douglas A, Sim B, Longley R, Edwards N . Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS One. 2013; 8(6):e65960. PMC: 3688861. DOI: 10.1371/journal.pone.0065960. View

Llewellyn D, Miura K, Fay M, Williams A, Murungi L, Shi J . Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria. Sci Rep. 2015; 5:14081. PMC: 4571651. DOI: 10.1038/srep14081. View

Douglas A, Andrews L, Draper S, Bojang K, Milligan P, Gilbert S . Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis. 2011; 203(9):1337-40. PMC: 3398130. DOI: 10.1093/infdis/jir033. View

Dutta S, Sullivan J, Grady K, Haynes J, Komisar J, Batchelor A . High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One. 2009; 4(12):e8138. PMC: 2780715. DOI: 10.1371/journal.pone.0008138. View

Miura K, Zhou H, Diouf A, Moretz S, Fay M, Miller L . Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol. 2009; 16(7):963-8. PMC: 2708396. DOI: 10.1128/CVI.00042-09. View

Remarque E, Faber B, Kocken C, Thomas A . Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008; 24(2):74-84. DOI: 10.1016/j.pt.2007.12.002. View

Polhemus M, Magill A, Cummings J, Kester K, Ockenhouse C, Lanar D . Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007; 25(21):4203-12. DOI: 10.1016/j.vaccine.2007.03.012. View

10.

Sanderson F, Andrews L, Douglas A, Hunt-Cooke A, Bejon P, Hill A . Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg. 2008; 78(6):878-83. View

11.

Caskey M, Klein F, Lorenzi J, Seaman M, West Jr A, Buckley N . Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522(7557):487-91. PMC: 4890714. DOI: 10.1038/nature14411. View

12.

Lawrence G, Cheng Q, Reed C, Taylor D, Stowers A, Cloonan N . Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000; 18(18):1925-31. DOI: 10.1016/s0264-410x(99)00444-2. View

13.

Dutta S, Lalitha P, Ware L, Barbosa A, Moch J, Vassell M . Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002; 70(6):3101-10. PMC: 127972. DOI: 10.1128/IAI.70.6.3101-3110.2002. View

14.

Roestenberg M, OHara G, Duncan C, Epstein J, Edwards N, Scholzen A . Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One. 2012; 7(6):e38434. PMC: 3372522. DOI: 10.1371/journal.pone.0038434. View

15.

Shekalaghe S, Rutaihwa M, Billingsley P, Chemba M, Daubenberger C, James E . Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014; 91(3):471-480. PMC: 4155546. DOI: 10.4269/ajtmh.14-0119. View

16.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C . DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013; 8(2):e55571. PMC: 3573028. DOI: 10.1371/journal.pone.0055571. View

17.

Laurens M, Thera M, Coulibaly D, Ouattara A, Kone A, Guindo A . Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013; 8(11):e79323. PMC: 3832522. DOI: 10.1371/journal.pone.0079323. View

18.

Douglas A, Edwards N, Duncan C, Thompson F, Sheehy S, OHara G . Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis. 2013; 208(2):340-5. PMC: 3685228. DOI: 10.1093/infdis/jit156. View

19.

Thera M, Doumbo O, Coulibaly D, Laurens M, Ouattara A, Kone A . A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011; 365(11):1004-13. PMC: 3242358. DOI: 10.1056/NEJMoa1008115. View

20.

Duncan C, Sheehy S, Ewer K, Douglas A, Collins K, Halstead F . Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011; 6(7):e22271. PMC: 3142129. DOI: 10.1371/journal.pone.0022271. View